An observational study in Breast Cancer, sponsored by RenJi Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by RenJi Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Breast Neoplasms by RenJi Hospital — 15 open to participants now, 17 under way, 2 of them phase 3. Breast Neoplasms · RenJi Hospital.
Among the 20 studies in Breast Neoplasms by RenJi Hospital, this one is one of 5 that started in 2023, is one of 7 observational ones, reaches primary completion later than 12 of the 16 other live ones, and was the 13th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →15 of the 20 studies in Breast Neoplasms by RenJi Hospital are open now, in 1 country. Recruiting first, the newest first:
RenJi Hospital · Sites in China
Ages 18+
RenJi Hospital · Sites in China
Ages 18–70 · Women only
RenJi Hospital · Sites in China
Ages 18–75 · Women only
RenJi Hospital · Sites in China
Ages 18+
RenJi Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 2
First in 2016; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 143 across the 13 interventional studies, 172 across the 7 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.
7 of the studies in Breast Neoplasms by RenJi Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06715826RenJi HospitalTarget-specific immunoPET Imaging of Breast Cancer | 2026-11 |
| NCT05831878RenJi HospitalRC48-ADC in HER2-low Advanced Breast Cancer | 2026-12 |
| NCT07396324RenJi HospitalNeoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer | 2026-12 |
| NCT07283692RenJi HospitalNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | 2026-12 |
| NCT06301438RenJi HospitalDalpiciclib in HR+/HER2- ABC | 2027-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 20 studies in Breast Neoplasms by RenJi Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
breast cancer patients with prior or current use of Disitamab vedotin (RC48-ADC)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RC48-ADC for breast cancer
Drug: Disitamab vedotin
recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Also known as: RC48-ADC
Progression-Free Survival
The time from the date of starting Disitamab Vedotin to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.
Time frame: From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years)
Adverse events
Adverse events during Disitamab Vedotin regimen will be assessed according to the NCI CTCAE v5.0.
Time frame: From the date of starting Disitamab vedotin to the end of the treatment (up to approximately 1 year)
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Mar 2027, 45 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 45 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.